Omnicell , Inc. (NASDAQ:OMCL), a leading provider of medication management solutions in the healthcare technology sector, has been navigating a complex market environment characterized by both ...

Omnicell (OMCL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

In the latest quarter, 4 analysts provided ratings for Omnicell OMCL, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the ...

Omnicell, Inc. OMCL has witnessed strong momentum in the past year. Shares of the company have risen 41.6% against a 11.3% decline of the industry during the same time frame. The S&P 500 composite ...

OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning. Omnicell ( NASDAQ:OMCL ) Full ...

Omnicell stock opened at $36.99 on Thursday. The stock has a market cap of $1.73 billion, a P/E ratio of 137.01, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a ...

FORT WORTH, Texas (AP) — FORT WORTH, Texas (AP) — Omnicell Inc. (OMCL) on Thursday reported fourth-quarter profit of $15.8 million. On a per-share basis, the Fort Worth, Texas-based company ...

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and ...